Role of Industry in Clinical Care, Research and Education

Rev 10/21/2014

APGO Interaction with Industry: A Medical Student Guide

OverviewThis presentation discusses the role of industry in

clinical care, biomedical research and health care provider education.

It can be a useful resource for multidisciplinary teams within your institution.

Objectives

Discuss industry’s contributions to clinical care, research and education.

Discuss the role of industry in the development of new drugs and medical devices and in the advancement of clinical care.

Compare sources of support for the advancement of clinical care.

At the completion of this presentation, participants will be able to:

Contributions to Clinical CareSignificant contributions to local, regional, national

and global health programs

Provision of low-cost or free medications or devices to millions of patients around the globe

Role of Industry in Healthcare Advancement

Performs research to advance diagnosis and treatment of disease

Provides financial support to other organizations for research

Stimulates and executes continuous development and improvement in drugs and devices

Provides funding for health care provider educational programs, especially CME

Investment by Industry to Bring New Drugs or Devices to the US Market

(hyperlinks will be active in presentation mode)

According to Forbes, August 2013, the cost to bring a new drug to market is estimated at $5 billion. http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new

-drugs-is-shaping-the-future-of-medicine/

Process to bring a new drug or device to market is long and complex Go to

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm to learn what it takes to bring a new drug to market

Go to http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm to learn what it takes to bring a new medical device to market

Contributions to ResearchBiomedical research expenditures by industry

exceed that of the Federal government.

In 2010, JAMA reported that by 2007, industry contributed the most money to biomedical researchIndustry = 58%NIH = 27%State and local governments = 5%Non Federal sources = 5%Not-for-profit = 4%

JAMA. 2010;303(2):137-143. doi:10.1001/jama.2009.1987

Date of download: 7/9/2014Copyright © 2014 American Medical Association.

All rights reserved.

From: Funding of US Biomedical Research, 2003-2008

JAMA. 2010;303(2):137-143. doi:10.1001/jama.2009.1987

Contributions to Education(hyperlinks will be active in presentation mode)

Approximately 40% of clinical departments receive funding for resident and fellowship training Grants Devices, supplies

Training time with industry representatives is necessary when new products or procedures are being introduced to healthcare providers

As of 2006, approximately 62% of medical school CME income comes from commercial support http://www.ohsu.edu/xd/about/services/integrity/coi/gifts/upload/Financia

l-Support-of-Continuing-Medical-Education.pdf

As of 2012, 35-40% of CME delivered to healthcare professionals was funded by unrestricted educational grants from the pharmaceutical industry where pharma companies are not permitted to have any influence whatsoever on the content http://www.pm360online.com/why-pharma-should-continue-to-support-certified-cme

/

Promotional Spend by Industry is on the Decline

http://www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdf Accessed 5/8/14

In 2012 we saw a greater overall drop in promotional spending than we observed the previous year, with 90% of decline attributable to detailing, sampling, and DTC. Spending in nearly every channel saw decline year over year in 2012, the only exception being mailings, which continued an upward trend.

Where Pharma is Investing their Promotional Dollars

http://www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdf Accessed 5/8/14